

HR 3154

Infectious Diseases Research and Development Act of 2005

Congress: 109 (2005–2007, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 30, 2005

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jul 29, 2005)

Official Text: <https://www.congress.gov/bill/109th-congress/house-bill/3154>

Sponsor

Name: Rep. Cubin, Barbara [R-WY-At Large]

Party: Republican • State: WY • Chamber: House

Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Baird, Brian [D-WA-3]	D · WA		Jun 30, 2005
Rep. Baker, Richard H. [R-LA-6]	R · LA		Jun 30, 2005
Rep. Bonner, Jo [R-AL-1]	R · AL		Jun 30, 2005
Rep. Davis, Artur [D-AL-7]	D · AL		Jun 30, 2005
Rep. Gingrey, Phil [R-GA-11]	R · GA		Jun 30, 2005
Rep. LaHood, Ray [R-IL-18]	R · IL		Jun 30, 2005
Rep. Matheson, Jim [D-UT-2]	D · UT		Jun 30, 2005
Rep. Weldon, Dave [R-FL-15]	R · FL		Jun 30, 2005

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 29, 2005
Judiciary Committee	House	Referred To	Jun 30, 2005
Ways and Means Committee	House	Referred To	Jun 30, 2005

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Infectious Diseases Research and Development Act of 2005 - Limits the liability of manufacturers of qualified infectious disease products by limiting: (1) punitive damages unless the manufacturer acted with malicious intent to injure the individual or deliberately failed to avoid unnecessary injury that the manufacturer knew the individual was substantially certain to suffer; and (2) non-economic damages to \$250,000.

Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.

Requires the Secretary of Health and Human Services to designate qualified infectious disease products as fast-track products for approval.

Amends the Public Health Service Act to require the Director of the National Institute of Allergy and Infectious Diseases to expand and intensify efforts to assist small manufacturers to conduct end-stage clinical trials on qualified infectious disease products.

Amends the Internal Revenue Code to establish an infectious disease research credit and a qualified infectious disease products manufacturing facilities investment credit.

Authorizes appropriations for activities related to antimicrobial resistance.

Establishes the Commission on Infectious Diseases Product Development to identify infectious pathogens that are a significant threat to public health and make recommendations to the Secretary on how best to address such pathogens.

Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary, acting through the Commissioner of Food and Drugs, to issue guidelines for the conduct of clinical trials with respect to antibiotic drugs.

---

## **Actions Timeline**

- **Jul 29, 2005:** Referred to the Subcommittee on Health.
- **Jun 30, 2005:** Introduced in House
- **Jun 30, 2005:** Introduced in House
- **Jun 30, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jun 30, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jun 30, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jun 30, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.